A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Conditions: Relapsed or Refractory Follicular Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Rituximab; Drug: Prednisone; Drug: Bendamustine; Drug: Lenalidomide; Drug: Fludarabine; Drug: Liso-cel Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials